We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Genetic Variants Associated with Unexplained Sudden Cardiac Death

By LabMedica International staff writers
Posted on 22 Jun 2021
As many as 450,000 Americans die every year from a sudden, fatal heart condition, and in slightly more than one in ten cases the cause remains unexplained even after an autopsy. More...
Most sudden cardiac deaths are caused by abnormal heart rhythms called arrhythmias and the most common life-threatening arrhythmia is ventricular fibrillation.

Unexplained sudden cardiac death (SCD) describes SCD with no cause identified. Genetic testing helps to diagnose inherited cardiac diseases in unexplained SCD. However, the associations between pathogenic or likely pathogenic (P/LP) variants of inherited cardiomyopathies (CMs) and arrhythmia syndromes have never been systematically examined.

Cardiovascular Scientists at the University of Maryland School of Medicine (Baltimore, MD, USA) and their many colleagues performed genetic sequencing in 413 patients, who died at age 41 on average of sudden unexplained heart failure. This genetic association study included 683 African American and White adults who died of unexplained SCD and were included in an autopsy registry. Overall, 413 individuals had DNA of acceptable quality for genetic sequencing. Data were collected from January 1995 to December 2015. A total of 30 CM genes and 38 arrhythmia genes were sequenced, and variants in these genes, curated as P/LP, were examined to study their frequency.

The team reported that the median (interquartile range) age at death of the 413 included individuals was 41 (29-48) years, 259 (62.7%) were men, and 208 (50.4%) were African American adults. A total of 76 patients (18.4%) with unexplained SCD carried variants considered P/LP for CM and arrhythmia genes. In total, 52 patients (12.6%) had 49 P/LP variants for CM, 22 (5.3%) carried 23 P/LP variants for arrhythmia, and two (0.5%) had P/LP variants for both CM and arrhythmia.

Overall, 41 P/LP variants for hypertrophic CM were found in 45 patients (10.9%), nine P/LP variants for dilated CM were found in 11 patients (2.7%), and 10 P/LP variants for long QT syndrome were found in 11 patients (2.7%). No significant difference was found in clinical and heart characteristics between individuals with or without P/LP variants. African American and White patients were equally likely to harbor P/LP variants.

Aloke Finn, MD, Clinical Associate Professor of Medicine and the senior author of the study, said, “Genetic screening isn't routinely used in cardiology, and far too many patients still die suddenly from a heart condition without having any previously established risk factors. We need to do more for them. What we found opens the door and asks some important questions. Should we be doing routine genetic screening in those who have a family history of unexplained sudden cardiac death?”

The authors concluded that in this large genetic association study of community cases of unexplained SCD, nearly 20% of patients carried P/LP variants, suggesting that genetics may contribute to a significant number of cases of unexplained SCD. The findings regarding both the association of unexplained SCD with CM genes and race-specific genetic variants suggest new avenues of study for this poorly understood entity. The study was published on June 2, 2021 in the journal JAMA Cardiology.

Related Links:
University of Maryland School of Medicine


Gold Member
Pharmacogenetics Panel
VeriDose Core Panel v2.0
Serological Pipet Controller
PIPETBOY GENIUS
New
cDNA Synthesis Kit
Ultimate cDNA Synthesis Kit
New
Whole Blood Control
Lyphochek Whole Blood Control
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: The tip optofluidic immunoassay platform enables rapid, multiplexed antibody profiling using only 1 μL of fingertip blood (Photo courtesy of hLife, DOI:10.1016/j.hlife.2025.04.005)

POC Diagnostic Platform Performs Immune Analysis Using One Drop of Fingertip Blood

As new COVID-19 variants continue to emerge and individuals accumulate complex histories of vaccination and infection, there is an urgent need for diagnostic tools that can quickly and accurately assess... Read more

Pathology

view channel
Image: Microscopy image of invasive breast cancer cells degrading their underlying extracellular matrix (Photo courtesy of University of Turku)

Visualization Tool Illuminates Breast Cancer Cell Migration to Suggest New Treatment Avenues

Patients with breast cancer who progress from ductal carcinoma in situ (DCIS) to invasive ductal carcinoma (IDC) face a significantly worse prognosis, as metastatic disease remains incurable.... Read more

Technology

view channel
Image: The machine learning-based method delivers near-perfect survival estimates for PAC patients (Photo courtesy of Shutterstock)

AI Method Predicts Overall Survival Rate of Prostate Cancer Patients

Prostate adenocarcinoma (PAC) accounts for 99% of prostate cancer diagnoses and is the second most common cancer in men globally after skin cancer. With more than 3.3 million men in the United States diagnosed... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.